Accelerating acquisitions and partnerships by innovative drugmakers to move away from dependence on long-listed products

A structural shift in the industry, as innovative drugmakers move away from dependence on long-listed products and accelerate acquisitions, partnerships with domestic and overseas companies, and outsourcing to develop novel modalities and next-generation innovative drugs.